Brentuximab vedotin and Tacrolimus Extended-Release Tablets
Determining the interaction of Brentuximab vedotin and Tacrolimus Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Tacrolimus may increase the blood levels of brentuximab vedotin. This may increase the risk and/or severity of side effects such as nausea, vomiting, diarrhea, nerve damage, and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, numbness or tingling in the hands and feet, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. In vitro, MMAE was found to be a substrate of the P-gp efflux transporter.
MANAGEMENT: Caution is advised when brentuximab is used with P-gp inhibitors. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended.
- "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA.
Generic Name: brentuximab
Brand name: Adcetris
Synonyms: Brentuximab Vedotin
Generic Name: tacrolimus
Brand name: Astagraf XL, Envarsus XR, Prograf, Hecoria
Synonyms: Tacrolimus (oral and injection), Tacrolimus (Systemic)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Brentuximab vedotin-Tacrolimus Granules for Suspension
- Brentuximab vedotin-Tacrolimus Injection
- Brentuximab vedotin-Tacrolimus Intravenous
- Brentuximab vedotin-Tacrolimus oral and injection
- Brentuximab vedotin-Tacrolimus Oral, Intravenous
- Brentuximab vedotin-Tactinal
- Tacrolimus Extended-Release Tablets-Breo Ellipta
- Tacrolimus Extended-Release Tablets-Brethine
- Tacrolimus Extended-Release Tablets-Brethine Subcutaneous
- Tacrolimus Extended-Release Tablets-Bretylium
- Tacrolimus Extended-Release Tablets-Bretylium Injection
- Tacrolimus Extended-Release Tablets-Brevibloc